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Correlation between Banif classification, acute renal rejection scores
and reversal of rejection. The Banfi' classification of acute rejection is
based on histologic grades and scores for borderline changes, glomerular,
vascular, interstitial and tubular lesions. We reviewed 56 episodes of acute
rejection occurring in 44 kidney allograft recipients (30 cadaveric and 14
living donor transplants), comparing Banif classification to degree of
reversibility of rejection. Rejection reversal was defined as complete if
serum creatinine returned 25% of baseline, partial if creatinine was >
25% to < 75% of baseline, and irreversible if creatinine was  75% of
baseline or graft loss occurred. Eight biopsies were classified as borderline
(SUM score 1.6 0.5), 14 grade I (SUM score 3.3 0.4), 19 grade II(SUM score 4.2 0.3), and 15 grade III (SUM score 8.5 0.4). SUM
distinguished borderline and grade III rejections, but not grades I and II.
Clinically, grade and SUM score correlated with rejection reversal.
Complete reversal of rejection occurred in 93% of patients with grade I
rejection, while 47% of patients with grade III had irreversible rejection.
The mean SUM for complete reversal was 3.9 0.34 and was different
from SUM of partial (6.0 0.86) and irreversible (8.5 0.93), P < 0.006.
Meanwhile, vascular scores were similar for rejections with complete (0.9
0.2) or partial (1.0 0.4) reversal, but significantly higher in those with
irreversible rejection (3.0 0.4, P < 0.000). Likewise, mean scores for
tubulitis and interstitial inflammation were significantly higher for irreversible
rejection. Resolution of rejection by steroids was correlated to low vascular
score (steroid sensitive 0.65 0.25 vs. steroid resistant 1.42 0.18,P <0.01),
and low SUM score (steroid sensitive 3.7 0.5 vs. steroid resistant 5.22
0.43, P < 0.04). Neither scores for tubulitis nor interstitial cellular inflamma-
tion were predictive of steroid sensitivity. These data demonstrate that Banff
scoring has clinical relevance in predicting rejection reversal and has impli-
cations to first-line therapy of rejection episodes.
Renal biopsies play a critical role in the management of
transplant recipients. In recent years the value of renal allograft
biopsies to recipient care has been emphasized by the widespread
use of nephrotoxic immunosuppressants and other agents that
compound the difficulty in establishing the clinical diagnosis of
renal dysfunction episodes [1—4]. Such difficulty has been docu-
mented in studies demonstrating the wide variation between
clinical impressions and the histopathologic findings on examina-
tion of renal tissue [5]. Yet despite their pivotal diagnostic role,
the utility of allograft biopsies in predicting rejection outcome has
been limited to reports correlating hemorrhagic and necrotizing
lesions to graft failure and to those reports relating outcome to
vascular involvement in rejection [5—7]. This may be in part
secondary to the subjective grading of histological lesions of
rejection and evaluation of the relative extent of injury of the
renal compartments targeted by rejection. Besides hindering the
predictive ability of allograft biopsies, the lack of standardization
of biopsy interpretation has made comparisons of rejection inci-
dence and treatment results between centers difficult. In addition,
the subjective nature of biopsy interpretation has become a major
problem in the design and analysis of multicenter transplant
studies aimed at developing new immunosuppressive agents and
immunosuppressive strategies.
Recognizing these problems, an international group composed
of physicians working in different fields of transplantation gener-
ated the "Banif Working Schema" for the standardization of
allograft biopsy interpretation [8]. The schema outlines histologic
criteria to grade rejection. Moreover, it provides an objective
semiquantitative estimation of the severity of renal injury. The
histologic lesions in the glomeruli, tubules, interstitium, and blood
vessels are graded on a scale of 0 to 3, then added to derive a
numerical score for rejection. The "Banif Working Classification"
provides a unique opportunity to explore the use of histologic
parameters of graft injury to guide anti-rejection treatment in a
prospective design based on the extent of morphologic evidence
of renal injury. Prospective protocols may reduce unnecessary
over or under immunosuppression, resulting in improved cost
control, graft survival, and ultimately patient care.
The "Banff Working Classification" was utilized in a group of
patients with renal allograft rejection. The aim was to examine
whether the classification accurately differentiates clinically rele-
vant grades of rejection. In addition, the clinical outcome of these
rejection episodes was correlated to the pathological grading and
scoring of the biopsies. This attempt represents one of the earliest
efforts to validate the new classification in clinical practice [9, 10].
Methods
Biopsy procedure and analysis
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Between January 1992 and October 1994 kidney allograft
biopsies examined in the Pathology laboratory of the University of
Tennessee-Memphis and diagnosed with rejection have been
evaluated according to the Banif Working Classification. An
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Fig. 1. Histopathologic features of acute renal allograft rejection (original magnification X400) (A). Acute glomerulitis characterized by endothelial
swelling and margination of circulating leukocytes within the glomerular capillaries (PAS). (B) Acute tubulitis of moderate grade (t2), a cross section
of renal tubules is infiltrated by 7 mononuclear cells (arrow), there is also diffuse interstitial inflammation (PAS). (C) Intimal arteritis with endothelial
proliferation and invasion of the intima by mononuclear inflammatory cells causing compromise of the arterial lumen (H&E).
adequate number of glomeruli (> 7) was required for inclusion in
the biopsy review. For this report, cases with rejection were
excluded if any of the following conditions existed: recipient's age
less than 18 years, evidence of chronic allograft nephropathy
defined by the presence of interstitial fibrosis and tubular atrophy,
with or without intimal arterial thickening, in greater than 20% of
the biopsy surface area, rejection episodes precipitated by treat-
ment noncompliance, or when anti-rejection treatment was initi-
ated prior to the biopsy. Allograft biopsies were performed with
ultrasound guidance, using the automatic spring-loaded core
biopsy system. Tissue samples were immediately divided, and one
part was fixed in Carson's fixative for paraffin embedding, using
standard processing techniques for light microscopy. A second
part of the biopsy was snap frozen in liquid nitrogen for immu-
nohistochemical studies, if needed. Serial 2 tm thin sections were
cut, and several sets, each composed of three slides, were stained
with hematoxylin and eosin, Periodic acid-Schiff, and Methena-
mine-silver, using standard staining techniques.
The slides were reviewed to grade the acute rejection and to
assign a numerical score for the different pathologic components,
according to the guidelines of the Banif Working Classification.
Briefly, four grades of rejection were described: very mild rejec-
tion (borderline) includes cases with mild interstitial inflammation
and mild tubulitis; Grade I (mild rejection) is a cellular rejection
with interstitial infiltrate in more than 25% of the biopsy and with
moderate tubulitis; Grade II (moderate rejection) has a significant
interstitial inflammation, severe tubulitis and/or mild or moderate
intimal arteritis; Grade Ill (severe rejection) includes severe
intimal arteritis or evidence of focal infarction or interstitial
hemorrhage. The morphologic changes in the glomeruli (g),
interstitium (i), tubules (t) and arteries (v) (Fig. 1) were scored
semiquantitatively from 0 to 3 (Table 1). Numerical scores were
obtained after evaluation of series of levels on the biopsies. The
SUM score for acute rejection was the sum of scores for g + i +
+ V.
Immunosuppression and anti-rejection treatment
A quadruple, sequential immunosuppressive protocol utilizing
high-dose steroids, azathioprine, OKT3 or ATGAM, and cyclo-
sporine was used for all cadaveric recipients. Methylprednisolone
(500 mg), azathioprine (5 mg/kg), and OKT3 (5 ml) or ATGAM(1 g) were administered as the patient was anesthetized for
transplantation [11]. Methylprednisolone was decreased to 250
mg on the first postoperative day and to 125 mg on the second
postoperative day and prednisone was initiated on the third
postoperative day at a daily dose of 0.5 mg/kg and tapered to 0.2
mg/kg daily at three months post-transplant. Azathioprine was
also given daily at a dose of 2 mg/kg. Cyclosporine, initiated in all
patients by the third to seventh postoperative day, was begun at a
daily dose of 4 to 8 mg/kg and adjusted to maintain a whole blood
trough level of approximately 250 ng/ml (TDX whole blood
monoclonal). Anti-lymphocyte therapy was continued for seven to
ten days post-transplant. Prophylactic therapy for cytomegalovirus
included acyclovir (200 mg) orally three times daily for six weeks,
and fungal prophylaxis was accomplished with nystatin or oral
ketoconazole. Ketoconazole was continued indefinitely in some
patients in order to reduce the dose of cyclosporine necessary to
maintain therapeutic cyclosporine levels. Identical triple immuno-
suppression without anti-lymphocyte induction was used in recip-
ients of live donor allografts except when the recipient was highly
sensitized, in which case quadruple therapy was used.
Renal allograft biopsies were performed when there was an
acute rise in the serum creatinine of  0.3 mg/dl, in the absence
of pre- or post-renal causes of graft dysfunction. Recipients with
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Table 1. Semiquantitative scoring for acute renal allograft rejection
according to the Banif Classification
Numeric
score Description
Glomerular (g) 0, 1, 2, 3 no, mild, moderate, severe glomerulitis
(g 3 = mononuclear cells in capillaries
of all or nearly all glomeruli with endothelial
enlargment and luminal occlusion)
Interstitial (i) 0, 1, 2, 3 no, mild, moderate, severe interstitial
mononuclear and lymphocytic cell infiltration
(i 3 =
50% of parenchyma is inflamed)
Tubular (t) 0, 1, 2, 3 no, mild, moderate, severe tubulitis
(t 3 >10 mononuclear cell per tubule or
per 10 tubular cells in several tubules)
Vascular (v) 0, 1, 2, 3 no, mild, moderate, severe intimal arteritis
(v 3 = severe intimal arteritis and/or
transmural arteritis and/or hemorrhage
and recent infarction)
Adapted from: Banif working classification of kidney transplant pathol-
ogy. Kidney mt 44:411—422, 1993.
delayed graft function had routine biopsies on days 7 and 14
post-transplantation, then weekly for the duration of dysfunction.
Treatment of histologically-proven acute rejection was based on a
protocol which called for initial high-dose steroid pulses (10 mg/kg
of methyiprednisolone, maximum 500 mg/day) on three successive
days. Response to steroid treatment was defined as a drop in
serum creatinine of  0.3 mg/dl on a minimum of two successive
days accompanied by a doubling of urine output. For steroid
resistant rejections anti-lymphocyte therapy was instituted with
either OKT3 or ATGAM. OKT3 was given for 10 days at 5
mg/day i.v., and patients were monitored during therapy by
measurement of OKT3 serum levels and percent peripheral CD3
positive cells. ATGAM was used in patients with anti-OKT3
antibodies and was given at a dose of 1 g/i.v. for ten days. ATGAM
dosage was adjusted based on percent peripheral CD2 positive
T-lymphocytes.
Patients and clinical follow-up data
Clinical data, collected from the data base system of the
transplant service at the University of Tennessee (Transplant
Information Network, Medical Services Research Group, Inc.,
Memphis, TN, USA) included recipient demographics, data re-
lated to the clinical profile of the recipients at the time of
rejection, and the response to anti-rejection treatment. Recipient
demographics included age, sex, race, pre-transplant sensitization
as measured by reactivity to a panel of lymphocytes (PRA), and
number of HLA antigens matched to the donor. In addition, the
transplant type (living vs. cadaveric), transplant number, days to
onset of rejection from transplantation and whether post-trans-
plant delayed graft function (DGF) existed at the time of rejection
diagnosis were recorded. The degree of reversibility of the
rejection was determined by comparing the serum creatinine level
measured two weeks after completion of anti-rejection treatment
(post-treatment creatinine) to the stable baseline serum creati-
nine prior to the rejection episode (pre-rejection creatinine). To
be considered a complete reversal of rejection, a return of
post-treatment creatinine to within 125% of the pre-treatment
level was required. In patients with post-transplant DGF, corn-
plete reversal of rejection was defined as biopsy-proven resolution
of rejection or resumption of renal function and achievement of a
normal serum creatinine. A partial resolution of rejection was
defined as a post-treatment creatinine improvement following
anti-rejection treatment but only achieving 126 to 175% of the
pre-treatment baseline serum creatinine. In patients with DGF,
partial resolution of rejection was defined as recovery of renal
function with a decline in serum creatinine but failure to reach
normal levels or as the persistence of milder rejection on repeat
biopsy. Rejection was considered to be irreversible if the post-
treatment creatinine was more than 175% of the pre-treatment
serum creatinine or if loss of graft function occurred. Non-
resolution of rejection changes on follow-up biopsies for persis-
tent DGF was also considered irreversible rejection.
Statistical analysis
Comparisons were made between the grades and scores for
acute rejection and the previously defined parameters of steroid
sensitivity and reversibility. Statistical analysis was performed
using a microcomputer software program, JMP® Version 2.0.5
Software for Statistical Visualization on the Apple® Macintosh®
(SAS Institute Inc., Cary, NC, USA). One-way analysis of variance
was used to determine the difference between groups as means
comparisons. Student's I-test was used to evaluate differences
between individual groups. Chi-square was used to compare
categorical data. Results were considered to be of statistical
significance for P values < 0.05.
Results
The fifty-six rejection episodes in the study occurred in 44
patients, with 12 recipients having more than one rejection
episode. The cohort of recipients included 21 African Americans
and 23 Caucasians; 30 (68%) were males; age ranged from 18 to
68 years (mean 40 years); the mean peak PRA was 17 5%
(range, 0 to 95). Twenty-six (59%) of the 44 kidney allografts were
procured from a cadaveric source and thirteen (30%) from a
living related donor. Four were combined kidney-pancreas cadav-
eric allografts, and one was from a live unrelated donor. The mean
HLA antigen match was 2 with a range of 0 to 4 antigens matched.
The average cold ischemia time for cadaveric kidneys was 23.0
1.5 hours, and two patients had received a previous kidney
transplant. Rejection occurred a mean of 167 43 days after
transplantation (range, 5 to 1710 days, median 41 days). The
average percent rise in serum creatinine from baseline was 37
3% (mean sEM) at the time of biopsy. At the time of rejection
diagnosis, the mean cyclosporine A (CsA) level was 199 15
ng/dl, and patients were receiving an average of 105 5 mg/day
of azathioprine and 25 2 mg/day of prednisone. One patient was
not receiving steroids, four were in the process of being withdrawn
from steroids, and three were not receiving Irnuran. Three
patients had low (<25 ng/dl) CsA levels, two had not started CsA,
and one had severe diarrhea resulting in decreased CsA absorp-
tion.
Pathological scoring
Of the 56 biopsies examined, 8 were classified as demonstrating
borderline changes, 14 had mild rejection (Grade 1), 19 had
moderate rejection (Grade II), and 15 had severe rejection
(Grade III). Table 2 outlines the Banif numerical scoring for the
biopsies according to the pathologic grade of rejection. The mean
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Based on the reversibility criteria described previ
(77%) rejection episodes were completely reversed, while seven
(13%) had a partial reversal, and six (11%) episodes were
classified as irreversible with three graft losses. Histologic grading
of rejection correlated with rejection reversal (P < 0.001, Table
3). Complete reversal of rejection occurred in all episodes of
rejection classified as borderline, in 93% of patients with Grade I
rejection, and in 79% of Grade II rejections. However, only 47%
of Grade III rejections were completely reversed while 40% were
irreversible (Fig. 2). Reversibility of rejection correlated with the
SUM scores. Complete rejection reversal was associated with
significantly lower SUM scores (3.03 0.34) than seen in episodes
with partial (6.0 0.86) or irreversible (8.50 0.93) rejection
(Table 4).
To further establish which of the morphologic features of
rejection correlated with reversibility, we analyzed the relation-
ship between the score of each morphologic component and
clinical outcome (Table 4). Glomerular scores were not different
for Irreversible rejection and Complete Reversal of rejection
(0.83 0.38 vs. 0.40 0.14, respectively, P = 0.5254). In contrast,
mean vascular scores were significantly higher (3.00 0.40 vs.
0.91 0.15, P < 0.0000) for irreversible rejections compared to
those with complete reversal.
Steroid therapy alone completely reversed rejection in 46% of
Fig. 2. Relationship between histologic grading of rejection and rejection
reversal. Symbols are: (iii) Grade III, (U) Grade II; (U) Grade I; (U)
Borderline.
all rejections graded as borderline, Grade I, or Grade II; and
reversed only one (17%) Grade III rejection episode (Fig. 3). The
remaining Grade III (N = 14) rejections required the addition of
anti-lymphocyte antibody therapy. Thus, steroid therapy alone
was successful in completely reversing rejection in only 36% of all
episodes in this study. Glomerular scores were somewhat higher
in patients who did not respond to steroids (0.64 0.15 vs. 0.15
0.20, P = 0.054; Table 5), while interstitial and tubular scores were
not significantly different between steroid sensitive and steroid
resistant rejections. However, the vascular scores were more than
doubled in steroid non-responders versus responders (P = 0.016),
and the total SUM score was significantly higher in steroid
non-responders (mean SUM of responders = 3.7 0.6 vs. 5.22
0.43 in non-responders P < 0.4). Of the 36 rejection episodes
determined to be unresponsive to steroid therapy, 31(86%) were
successfully treated with anti-lymphocyte antibody therapy. The
rejection episodes that failed anti-lymphocyte therapy were two
Steroid Steroid
sensitive resistent
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Table 4. Relationship between pathological scoring of rejection and outcome
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Fig. 3. Relationship between pathological scoring and reversibility of rejec-
tion by steroids alone. Symbols are: (E1) vascular; () tubular; (U)
interstitial; (U) glomeruli.
Grade II and three Grade III rejections. Interestingly, there was a
significantly higher tubular score for these anti-lymphocyte non-
responders (1.00 0.16 for anti-lymphocyte responders vs. 2.2
0.4 for non-responders, P = 0.0094).
Discussion
This report summarizes an attempt to test the usefulness of the
Banif Working Classification in clinical practice. The data dem-
onstrate that the Banif classification and scoring system differen-
tiates clinically relevant grades of rejection, and that the total
SUM score of acute rejection and the vascular score are the
strongest correlates to rejection reversibility. Acute tubulointer-
stitial rejections with a SUM score less than 4 are most likely
reversible and steroid responsive, while most vascular rejections
are steroid resistant. A SUM score equal to or greater than 6 is
associated with an increased likelihood of steroid resistance or
irreversibility of the rejection. Conventional anti-rejection treat-
ment (steroids and antilymphocyte agents) failure occurred in
greater than one-half of Grade III acute rejection and in those
rejections with a vascular score of 3. These results indicate that
using the Banif schema allows for objective semiquantitation of
the histological lesions and provides clinically useful information
to guide anti-rejection therapy and predict rejection outcome.
Prior to the introduction of the Banif Schema, there were
several attempts to devise an acute rejection index [12, 13].
Finkeistein et al [12] based their index on semi-quantitative
analysis of nine histologic features summing rejection changes and
their effect on graft structure. They defined scoring levels that
were indicative of acute rejection and demonstrated that response
to therapy was predicted by histology. Prediction of response to
anti-rejection treatment was, however, subjectively based on the
pathologist's overall impression. Similarly, Parfrey et al [51 pro-
posed morphologic, clinical, and combined clinical and morpho-
logic indices to predict rejection outcome. The morphologic index
devised by Parfrey had a negative predictive value, that is,
histologic features of graft injury were a better predictor of return
to dialysis than clinical parameters of renal function during
rejection. The combination of both clinical and morphologic data
improved the prediction of graft outcome. In the Banif Schema,
the summation scores of tubular, interstitial, and vascular lesions
are equivalent to the previously reported acute rejection index.
Scoring in the Banif Schema is more detailed, encompassing all
possible morphologic variables and grades. Moreover, more spe-
cific guidelines have been described for scoring by the Banif
criteria, making it more objective and easier to apply than
previously-described rejection indices. In addition, a recent report
has demonstrated the schema to be reproducible among the study
Banif group pathologists [9].
The relative importance of the severity and distribution of
rejection pathology in the various renal compartments and their
relation to rejection resolution is reflected in the semiquantitative
scoring of the Banif Schema. Intimal arteritis and tubulitis are
recognized as the principal indicators of acute rejection. The
severity of infiltration of the renal tubules by mononuclear
inflammatory cells, that is, tubulitis, differentiates tubulointersti-
tial rejection from mild inflammation characterized as borderline
changes, while the presence of intimal arteritis upgrades acute
rejection to either moderate or severe, regardless of the severity
of the interstitial inflammation. Stressing vascular changes in
rejection grading is based on studies that identified intimal
arteritis as pathognomonic for acute rejection [15—17], and on
evidence that the biological behavior of vascular rejection is quite
different from that of pure cellular rejection [12, 13, 18]. It has
been shown that the one-year graft survival for patients with
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Table 5. Ability to reverse rejection by steroids alone
Reversal by
steroids alone SUM Glomeruli Interstitial Tubular Vascular
Yes, N = 20 3.70 0.58 0.15 0.20 1.85 0.22 1.05 0.23 0.65 0.25
No, N = 36 5.22 0.43" 0.64 0.15 1.94 0.16 1.22 0.17 1.42 0.18"
ap = 0.0408
"p = 0.0155, ANOVA
vascular rejection is significantly lower than in those with predom-
inantly cellular inflammation and that severe vascular changes are
consistent predictors for graft failure [19, 20]. Furthermore, the
presence of vascular changes affects the rate of rejection reversal,
even in the context of newer, more potent anti-rejection therapies
[21—23].
Tubulitis is a reliable indicator of tubulointerstitial rejection,
but its impact on functional recovery of the allograft has not been
adequately studied. The presence of severe tubular necrosis
enhanced the negative predictability of vascular pathology during
the course of acute rejection [5]. Recent evidence suggests that
renal tubules are not equally involved by cellular rejection and
that both the distal convoluted tubules and the collecting ducts are
more vulnerable to invasion by T-lymphocytes [22]. The Banif
schema accommodates this segmental variation in tubular inflam-
mation during rejection, as the severity of tubulitis is determined
by the number of invading inflammatory mononuclear cells in the
most affected tubule. In the current study, the tubulitis scores
appeared to parallel the increasing grade of rejection, with Grade
III rejection demonstrating significantly higher tubulitis scores
than other grades. Mild tubulitis was associated with complete
rejection reversal, while severe tubulitis was significantly more
pronounced in patients who failed anti-lymphocyte therapy.
Although scoring for glomerular inflammatory lesions has been
incorporated into the Banif Schema, it was stated that the
significance of the glomerulitis was not clear. Rejection glomeru-
litis is defined by endothelial swelling, intraglomerular margin-
ation of mononuclear cells, and glomerular thrombosis or necrosis
[24, 25]. This pattern of allograft glomerulitis was initially de-
scribed in recipients with cytomegalovirus (CMV) infection and,
thus, was thought to be a CMV-associated glomerulopathy [26].
Now, it is widely accepted that acute allograft glomerulopathy is a
distinctive form of transplant rejection, that may be modified or
induced in some recipients by a CMV infection [27, 28]. Although
slightly higher glomerular scores were found in steroid-resistant
rejection and in Grade III rejections, acute allograft glomerulitis
was not frequently found in our biopsies and did not statistically
correlate with rejection outcome.
The application of the Banif Schema in clinical practice is not
without problems. As with all new pathology-based criteria,
uniform application and acceptance requires increased clinical
experience and demonstration of validity in everyday clinical
practice. To date, attempts at validating the utility of Banif
Schema have yielded encouraging reproducibility of results. Al-
though the initial Banif report did not suggest summing of the
scores for various rejection histologies, this study as well as the
body of literature have used SUM scores to differentiate rejection
grades. Conceptually the use of SUM scores could be problematic
by giving equal weight to rejection lesions of various significance
and may complicate the ability to differentiate clinically relevant
rejection grades. Routine use of Banif Schema in clinical practice
has identified some areas of additional potential problems, par-
ticularly the overlap between mild and moderate rejection by
SUM scores. This overlap is further compounded by the fact that
SUM scores do not distinguish cellular rejection with a heavy
cellular infiltrate from vascular rejection, although these two
forms of rejection may have very different outcomes. This may be
clinically important, particularly as it has been shown that pure
cellular rejection, even with heavy interstitial inflammation, does
not preclude functional recovery of the allograft and that inter-
stitial inflammation is present in a prominent proportion of stable
renal grafts without a detrimental impact on long-term function or
survival [29—31]. For example, a SUM score of 5 can be obtained
in biopsies with the following rejection features: (Example 1) c =
1, t = 2, v = 2; (Example 2) c = 2, t = 2, v = 1; (Example 3) c =
3, t 2, v = 0. Because of the variations in rejection severity in the
renal compartments, the biological behavior of these rejections
(one predominantly vascular, Example 1; the other cellular,
Example 3) is expected to be diverse [7] despite identical scoring
on the Banif Schema. Therefore, at the present time, interpreta-
tion of the semi-quantitative results from Banif Schema should be
done utilizing the collective information on grade, SUM score,
and vascular score.
In conclusion, this study demonstrates that the histologic pa-
rameters of rejection graded according to the Banif Schema can
be predictors of rejection outcome. A severe vascular rejection
with a score of 3 and a SUM score of 6 or greater is likely to be
steroid-resistant and more likely to have incomplete reversal, even
with anti-lymphocyte therapy. On the other hand, the prognosis of
a moderate tubulointerstitial rejection is dependent on the pres-
ence of associated vascular injury and the total score of rejection.
Further work is needed to eliminate potential overlap in Banif
grading and scoring and to further enhance the clinically utility of
the schema.
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